Genetic testing for BRIP1 germline mutations in breast cancer cases with a strong family history can contribute to clinical management 3 through early detection, prevention measures, and therapeutic selection. This clinical utility is controversial in the case of "variants of unknown significance," (VUS).
Splicing alteration is usually assigned to flanking exon-intron boundary variants, but single nucleotide substitutions in exonic regions can also affect the mRNA processing. 4 The mechanism could be based on creating novel splicing enhancers sites, or activating cryptic splicing sites. 5 Since the management of VUS in moderate-penetrance genes like BRIP1 is a challenge, evaluating their potential splicing alteration has to be encouraged. 
| Detection of point mutations
The probands II.1 and IV.2 were recruited through Genetic Counseling and specifically screened for the c.550G>T mutation by Sanger sequencing.
To discard any other cause of splicing alteration, exonic and flanking intronic regions of exons 4, 5, 6, and 7 of BRIP1 were sequenced with the BigDye Terminator Sequencing Kit v3.1 (Applied Biosystems, Foster City, CA) on an ABI 3100 DNA sequencer (Applied Biosystems). Furthermore, the entire intron 5 was sequenced in order to discard any other distant splicing variant. The 320-control group was screened for c.550G>T mutation by High Resolution Melting Analysis in LightCycler480 (Roche, Basilea, Suiza). Mutation nomenclature was based on the NM_032043.2 GenBank reference sequence.
| Detection of large genomic rearrangements (LGRs)
Multiplex ligation-dependent probe amplification (MLPA) analysis with SALSA P240-A2 BRIP1/CHEK1 Kit (MRC-Holland, Amsterdam, the Netherlands) was used to discard any germline LGR in the index case.
The PCR products were separated by electrophoresis on an ABI3130
and analyzed by the MRC Coffalyser software (MRC-Holland).
| RNA isolation and RT-PCR
RNA was extracted from peripheral blood lymphocytes using the Products were separated in low melting 2% agarose gel and visualized with Red Safe TM staining. Isolated bands were extracted using NucleoSpin ® Gel and PCR Clean-up (Macherey-Nagel, Düren, Germany) and subsequently sequenced. 3 | RESULTS
| Mutation identification
A missense mutation c.550G>T (p.Asp184Tyr) in the BRIP1 suppressor gene was identified in a Breast Cancer family (Figure 1 ). This variant was also identified in Breast Cancer and Lynch Syndrome families. 
| Variant In silico analysis
Concerning BRIP1 protein, c.550G>T variant replaces aspartic acid with tyrosine at codon 184 (p.Asp184Tyr). In silico analyses suggest that the amino acid change is likely to be harmful at a structural and functional protein level: SIFT "Deleterious," PolyPhen-2 "Probably
Damaging." In addition to the predictions related to the amino acid change, we also evaluated its potential effect on splicing. In this respect, HSF predicts a new donor splicing enhancer site. Specifically,
ESE finder indicates that the missense variant breaks an Exonic Splicing
Enhancer site (ESE) used by SRSF2, thus the recruitment of the splicing machinery could be affected.
| RT-PCR analysis
To confirm HSF and ESE predictions BRIP1 transcript including exons 4, 5, 6, and 7 was amplified by RT-PCR. Interestingly, mutation carriers transcripts revealed two bands: a 585 basepairs (bp) band corresponding with the expected wildtype fragment and an aberrant transcript band (464 bp), while controls only showed the wild-type band. The RT-PCR products from one of the carriers and one of the controls can be compared in Figure 2A . The presence of an aberrant transcript band endorses the splicing alteration predicted but the most striking result was the exon 5 skipping revealed by sequencing (Figure 2A ). To guarantee the splicing event, we performed the RT-PCR using the RNA of the other carrier evidencing the same pattern ( Figure 2B ). To confirm exon 5 skipping, we designed a forward primer overlapping exons 4 and 6. Hypothetically, the primer only matched an aberrant transcript without exon 5, where the transition from the sequence of exon 4 and 6 took place. We carried out a PCR using the primer that sits in between exon 4 and 6 (4/6 Fw: 5′ CAACTTGTCAAGATTA-GAAAACG 3′) and the 7 reverse primer with the RT-PCR products as template. Only the carrier sample showed the 303 bp PCR product ( Figure 2B ).
| LGRs and other point mutations
Considering that an exon 5 germline deletion in heterozygosis could explain the observed result, we carried out a MLPA. No large genomic rearrangements were detected (Supplemental figure S1 ).
In addition, neither the entire 5-6 intron nor intronic flanking regions of exons 4, 5, 6, and 7 showed variants that could be responsible for exon 5 skipping.
| Segregation studies
We investigated if the c.550G>T BRIP1 variant segregated with Breast
Cancer phenotype in the family (Figure 1 ). Among the three affected women, only two were available; both of them carried the mutation.
On the other hand, another three women carried the mutation but, as far as we know, none of them had developed cancer. The family study suggests an incomplete segregation, typical of low-penetrance cancer genes, which could be conferring a significant risk in this pedigree with several breast and prostate cancer cases. A VUS in BRIP1, c.550G>T (p.Asp184Tyr), was detected in a Breast
Cancer family. This is a rare missense variant according with the low frequency in population databases (rs201047375, ExAC 0. 016%) and the absence in our control group (320 samples). It has been previously reported in other cancer studies but neither segregation analysis nor functional assays has been performed.
Considering any mutation could potentially modify the splicing process, 4, 10 we examined the variant with HSF and ESE finder tools. As a result, an alteration of an ESE was predicted, a possible underlying cause of anomalous exon skipping. In fact, SR proteins are wellcharacterized RNA binding proteins that promote exon inclusion by binding to ESEs. 11 According with this hypothesis, we performed a transcript analysis revealing an aberrant band. Intriguingly, the sequencing of this band confirmed an exon 5 skipping. This event could be consistent with the inactivation of the ESEs placed on the adjacent exon. 12 It is suggested that the SRSF2 protein would be regulating exon 5 inclusion through its interaction with the ESEs placed on exon 6. Consequently, when the ESE is disrupted, SRSF2 fails to recruit splice machinery and the exon 5 skipping happens.
To reinforce the assumption that c.550G>T BRIP1 variant is responsible for the discovered splicing disruption, it seems essential to exclude any other genetic cause. For this purpose, firstly we had corroborated no genomic exon 5 deletion using MLPA; secondly, we had further checked the entire 5-6 intron sequence and intronic flanking sequence of exons 4, 5, 6, and 7, ruling out any other concerning splice variant.
These results support the hypothesis that the VUS changes the sequence of an ESE element in exon 6, disrupting the splicing. This statement would be consistent with the exon 5 skipping observed in both mutation carriers.
At protein level, exon 5 encodes part of the Helicase ATP-binding domain, 13 suggesting a probably impairment of protein function which could affect the DNA repair efficiency and, consequently, modulate Breast Cancer risk. To further argue the relationship between the c.550G>T BRIP1 mutation and Breast Cancer predisposition, RNA binding assays and functional studies will be required.
As a consequence of BRIP1 disruption, it may be inferred a sensitivity of the carriers to chemotherapeutic agents like PARP inhibitors. 14 As far as we know, this is the first attempt to prove the in silico prediction of c.550G>T BRIP1 mutation. The analysis at RNA level confirms an exon 5 skipping, probably as a result of the creation of a new enhancer donor site of splicing. It is worth noting that an exonic variant located in exon 6 has an impact on exon 5, highlighting the complexity of the spliceosome machinery.
| CONCLUSIONS
In this report, we describe a Hereditary Breast Cancer family with a VUS in BRIP1. The cDNA study indicates that the variant completely abolishes normal splicing by creating a novel 5′ splice enhancer site, which led to a novel transcript without exon 5.
We have contributed to the molecular characterization of the c.550G>T BRIP1 mutation, classified as a VUS. Interestingly, the results support its pathogenicity due to the alteration of splicing rather than the amino acid substitution emphasizing how complex it is to define the contribution of missense variants to cancer predisposition and endorsing the studies at RNA level.
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